Chelsea's phase III trial of Northera for neurogenic orthostatic hypotension treatment meets primary endpoint - Clinical Trials
Links shared publicly online about this topic.
- 855total visits
Chelsea's phase III trial of Northera for neurogenic orthostatic hypotension treatment meets primary endpoint - Clinical Trials
Chelsea Therapeutics International, Ltd. announced that preliminary analyses of its phase III Northera Study 301 met its primary endpoint.
View full resource at pharmabiz.com
Tags: Low Blood Pressure, Clinical Trial
Most Recently Shared on September 22, 2010 at 8:11 am By:
Chelsea's phase III trial of Northera for neurogenic orthostatic hypotension treatment meets primary endpoint: Che... http://bit.ly/d25CCj
Advertisement
